Biological
fIPV
fIPV is a biological therapy with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_3
2
50%
Ph phase_1
1
25%
Ph phase_4
1
25%
Phase Distribution
1
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)
Trials by Status
withdrawn125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_3
A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV
NCT03239496
completedphase_4
Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study
NCT03722004
completedphase_1
Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant
NCT03922061
withdrawnphase_3
A Study to Evaluate Immunogenicity of Various Schedules of Inactivated Polio Vaccine
NCT03016949
Clinical Trials (4)
Showing 4 of 4 trials
NCT03239496Phase 3
A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV
NCT03722004Phase 4
Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study
NCT03922061Phase 1
Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant
NCT03016949Phase 3
A Study to Evaluate Immunogenicity of Various Schedules of Inactivated Polio Vaccine
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4